Volume 13, Number 3—March 2007
Research
Worldwide Emergence of Extensively Drug-resistant Tuberculosis
Table 3
Pattern | No. tested | No. (%) resistant |
---|---|---|
Any resistance (total) | 3,520 | 1,542 (43.8) |
Aminoglycosides (AG)§ | 3,442 | 630 (18.3) |
Capreomycin (CM) | 2,743 | 279 (10.2) |
Fluoroquinolones (FQ) | 3,492 | 673 (19.3) |
Thioamides (TA) | 3,132 | 605 (19.3) |
Cycloserine (CS) | 2,615 | 141 (5.4) |
Para-aminosalicylic acid (PAS) | 2,860 | 450 (15.7) |
Extensively drug-resistant TB (XDR-TB, total)¶ | 3,520 | 347 (9.9) |
AG + CM + FQ | 2,656 | 90 (3.4) |
AG + CM + TA | 2,498 | 77 (3.1) |
CM + FQ + TA | 260 | 50 (19.2) |
AG + FQ + TA | 3,040 | 102 (3.4) |
AG + FQ + CS | 139 | 39 (28.1) |
FQ + TA + PAS | 2,505 | 94 (3.8) |
*Tested for ≥3 second-line drug classes; SRLs, Supranational Reference Laboratories.
†Not all isolates were tested for each second-line drug class (with the exception of the Republic of Korea SRL), so results are reported as a proportion of isolates tested to the specified class of drugs. For combination resistance patterns, results are reported as a proportion of isolates tested to all of the classes of drugs in the specific combination.
‡Cells are not mutually exclusive.
§Other than streptomycin (e.g., kanamycin, amikacin).
¶XDR-TB, extensively drug-resistant tuberculosis, i.e., multidrug-resistant tuberculosis (resistant to at least isoniazid and rifampin) with additional resistance to ≥3 classes of second-line drugs.
Page created: October 29, 2010
Page updated: October 29, 2010
Page reviewed: October 29, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.